Structure-based design, discovery and development of checkpoint kinase inhibitors as potential anticancer therapies
about
Trial Watch: Targeting ATM-CHK2 and ATR-CHK1 pathways for anticancer therapyBufalin induces cell death in human lung cancer cells through disruption of DNA damage response pathways.CHK2 kinase in the DNA damage response and beyondThe clinical development candidate CCT245737 is an orally active CHK1 inhibitor with preclinical activity in RAS mutant NSCLC and Eµ-MYC driven B-cell lymphoma.Targeting DNA Repair in Cancer: Beyond PARP Inhibitors.Targeting homologous recombination-mediated DNA repair in cancer.Quantitative structure-activity relationship: promising advances in drug discovery platforms.Small cell lung carcinoma cell line screen of etoposide/carboplatin plus a third agent.The hunt for antimitotic agents: an overview of structure-based design strategies.Targeting the ATR-CHK1 Axis in Cancer TherapyDeciphering the true antiproliferative target of an MK2 activation inhibitor in glioblastoma.Combining docking-based comparative intermolecular contacts analysis and k-nearest neighbor correlation for the discovery of new check point kinase 1 inhibitors.A unique gene expression signature is significantly differentially expressed in tumor-positive or tumor-negative sentinel lymph nodes in patients with melanoma.KPNA2 over-expression is a potential marker of prognosis and therapeutic sensitivity in colorectal cancer patients.Evaluation of the likelihood of a selective CHK1 inhibitor (LY2603618) to inhibit CYP2D6 with desipramine as a probe substrate in cancer patients.Expression of DNA doublestrand repair proteins in oral leukoplakia and the risk of malignant transformation.Synthesis and cytotoxic evaluation of novel quinazolinone derivatives as potential anticancer agents
P2860
Q26745686-D89423FD-69FC-456B-B6BE-AB08F21AE3D8Q34421829-9393143B-D90A-4C04-A487-AF327BF1A550Q34977480-53BFE4EC-FE7B-43BE-93CF-491211C00E54Q36771796-BFE70414-F499-46D6-913F-EEE1E4C5E987Q37634102-FB790D26-911D-4CBA-9972-F1B83D80F3B0Q38184667-45EF1E57-F0AA-4E9C-9A7A-89C4D9A7BDD5Q38584487-60E6606C-EC11-4421-B925-5398846EE7E3Q38695896-F0339169-3A03-48CF-AECD-34861548DD64Q38808120-E5F06195-C0A5-4353-829D-02A9EF76B853Q38817102-038D0864-B496-4F63-AF85-797DDDEF71C5Q39744761-B8D5325F-78CA-4498-B3A1-1D5D7B7195B6Q40959163-C95788F2-8853-47FE-8B39-C21ABBB6FC0BQ47792677-004A06E8-A2C7-4B61-979C-D6337A9FC1E8Q53245560-D5E140BF-0E01-4573-BF6D-115B796A9839Q54316808-59F21868-13B0-4210-8E3A-7A6569E71B1BQ55365913-4D8FEED6-149B-4112-8274-5E0A6C2EC5F1Q57062310-1CF39776-2E7C-427A-8BC6-EC5921CD97BE
P2860
Structure-based design, discovery and development of checkpoint kinase inhibitors as potential anticancer therapies
description
2013 nî lūn-bûn
@nan
2013 թուականի Յունիսին հրատարակուած գիտական յօդուած
@hyw
2013 թվականի հունիսին հրատարակված գիտական հոդված
@hy
2013年の論文
@ja
2013年学术文章
@wuu
2013年学术文章
@zh-cn
2013年学术文章
@zh-hans
2013年学术文章
@zh-my
2013年学术文章
@zh-sg
2013年學術文章
@yue
name
Structure-based design, discov ...... potential anticancer therapies
@ast
Structure-based design, discov ...... potential anticancer therapies
@en
Structure-based design, discov ...... potential anticancer therapies
@nl
type
label
Structure-based design, discov ...... potential anticancer therapies
@ast
Structure-based design, discov ...... potential anticancer therapies
@en
Structure-based design, discov ...... potential anticancer therapies
@nl
prefLabel
Structure-based design, discov ...... potential anticancer therapies
@ast
Structure-based design, discov ...... potential anticancer therapies
@en
Structure-based design, discov ...... potential anticancer therapies
@nl
P2093
P2860
P1476
Structure-based design, discov ...... potential anticancer therapies
@en
P2093
Alan M Jones
Ian Collins
Thomas P Matthews
P2860
P304
P356
10.1517/17460441.2013.788496
P407
P577
2013-06-01T00:00:00Z